化合物GZD 824 T3071
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
50 mg | 1257628-77-5 | ¥3,570.00 | 询底价 |
5 mg | 1257628-77-5 | ¥645.00 | 询底价 |
100 mg | 1257628-77-5 | ¥5,190.00 | 询底价 |
10 mg | 1257628-77-5 | ¥995.00 | 询底价 |
1 mL | 1257628-77-5 | ¥749.00 | 询底价 |
2 mg | 1257628-77-5 | ¥368.00 | 询底价 |
1 mg | 1257628-77-5 | ¥248.00 | 询底价 |
25 mg | 1257628-77-5 | ¥2,230.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Olverembatinib
描述: Olverembatinib (GZD 824) 是一种高效的、口服具有活性的pan-Bcr-Abl 抑制剂,具有抗肿瘤活性。它能广泛而有效地抑制突变型 Bcr-Abl。它对天然的 Bcr-Abl 和 Bcr-AblT315I 作用的IC50值分别为 0.34 nM 和 0.68 nM。
细胞实验: Cells in the logarithmic phase are plated in 96-well culture dishes. Twenty-four hours later, cells are treated with the corresponding compounds or vehicle control at the indicated concentration for 72 h. CCK-8 is added into the 96-well plates (10 μL/well) and incubated with the cells for 3 h. OD450 and OD650 are determined by a microplate reader. Absorbance rate (A) for each well is calculated as OD450 – OD650. The cell viability rate for each well is calculated as V% = (As – Ac)/(Ab – Ac) × 100%, and the data were further analyzed using Graphpad Prism5. The data are the mean value of the three experiments. As is the absorbance rate of the test compound well, Ac is the absorbance rate of the well without either cell or test compound, and Ab is the absorbance rate of the well with cell and vehicle control.(Only for Reference)
激酶实验: FRET-Based Z′-Lyte Assay Detecting Peptide Substrate Phosphorylation: The kinases ABL1, ABL1(E255K), ABL1 (G250E), ABL1(T315I), and ABL1(Y253F) are P3049, PV3864, PV3865, PV3866, and PV3863 are full-length human recombinant protein expressed in insect cells and histidine-tagged. Inhibition activities of inhibitors against Abl1 and its mutants are performed in 384-well plates using the FRET-based Z′-Lyte assay system. Briefly, the kinase substrate is diluted into 5 μL of kinase reaction buffer; and the kinase is added. Compounds (10 nL) with indicated concentrations are then delivered to the reaction by using Echo liquid handler, and the mixture is incubated for 30 min at room temperature. Then 5 μL of 2X ATP solution is added to initiate the reaction, and the mixture is further incubated for 2 h at room temperature. The resulting reactions contains 10 μM (for wild-type Abl1, and mutants Y253F, Q252H, M351T, and H396P) or 5 μM (for mutants E255K, G250E, T315I) of ATP, 2 μM of Tyr2 Peptide substrate in 50 mM HEPES (PH 7.5), 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.0247 μg/mL Abl1, and inhibitors as appropriate. Then, 5 μL of development reagent is added, and the mixture is incubated for 2 h at room temperature before 5 μL of stop solution is added. Fluorescence signal ratio of 445 nm (Coumarin)/520 nm (fluorescin) is examined on an EnVision Multilabel Reader. The data are analyzed using Graphpad Prism5. The data are the mean value of three experiments.
体外活性: GZD824 potently inhibits the growth of Ba/F3 cells expressing wildtype Bcr-Abl with IC50 of 1.0 nM. Highly consistent with biochemical kinase inhibition and tight protein binding affinity, GZD824 also strongly inhibits the proliferation of Ba/F3 cells expressing Bcr-AblT315I mutant and 14 other resistance-relevant Bcr-Abl mutants. In addition, GZD824 efficiently suppresses the activation of Bcr-Abl as well as downstream Crkl and STAT5 in a concentration-dependent manner in K562 CML cells. [1]
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 100 mg/mL (187.77 mM)
关键字: Bcr-Abl(T315I) | GZD824 | HQP 1351 | HQP1351 | inhibit | HQP-1351 | Inhibitor | linase | region-Abelson | imatinib | breakpoint | cluster | Olverembatinib | GZD-824 | nonphosphorylated | Bcr-Abl | resistance | phosphorylated
相关产品: Berbamine dihydrochloride | CpCDPK1/TgCDPK1-IN-1 | Masitinib | Bafetinib | Vamotinib | AT9283 | Adaphostin | MBM-55S | Gypsogenin | Bosutinib
相关库: Drug Repurposing Compound Library | Angiogenesis related Compound Library | Anti-Cancer Drug Library | Anti-Cancer Clinical Compound Library | Kinase Inhibitor Library | Inhibitor Library | Cytoskeletal Signaling Pathway Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Active Compound Library | Orally Active Compound Library
化合物GZD 824 T3071信息由TargetMol中国为您提供,如您想了解更多关于化合物GZD 824 T3071报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途